Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

What Will Happen to Anavex Life Sciences Corp

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
georgejjl Member Profile
 
Followed By 80
Posts 11,984
Boards Moderated 0
Alias Born 04/08/04
160x600 placeholder
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 6:00:00 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
Withdrawal of Registration Statement (ammendment) (aw) Edgar (US Regulatory) - 9/16/2019 4:17:42 PM
Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patie... GlobeNewswire Inc. - 9/16/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2019 5:11:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/13/2019 5:07:24 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 9/13/2019 5:02:44 PM
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Ret... GlobeNewswire Inc. - 9/4/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:07:28 PM
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 8/7/2019 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019 GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical... GlobeNewswire Inc. - 7/31/2019 7:00:00 AM
Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for... GlobeNewswire Inc. - 7/29/2019 7:00:00 AM
Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Respo... GlobeNewswire Inc. - 7/17/2019 11:45:00 AM
georgejjl   Sunday, 10/20/19 10:58:46 PM
Re: None
Post # of 223243 
What Will Happen to Anavex Life Sciences Corp (NASDAQ:AVXL) Next? The Stock Has Decline in Shorts
PATRICIA PEREZ
Anavex Life Sciences Corp. (NASDAQ:AVXL)

The stock of Anavex Life Sciences Corp (NASDAQ:AVXL) registered a decrease of 1.81% in short interest. AVXL’s total short interest was 4.06 million shares in October as published by FINRA. Its down 1.81% from 4.13 million shares, reported previously. With 501,800 shares average volume, it will take short sellers 8 days to cover their AVXL’s short positions.

It closed at $2.81 lastly. It is down 11.11% since October 20, 2018 and is downtrending. It has underperformed by 11.11% the S&P500.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of AlzheimerÂ’s disease, other central nervous system diseases, pain, and various cancers. The company has market cap of $147.95 million. The companyÂ’s lead drug candidates include ANAVEX 2-73, a Phase 2a clinical trial for the treatment of AlzheimerÂ’s disease; and preclinical stage to treat ParkinsonÂ’s disease. It currently has negative earnings. The Company’s preclinical drug candidates include ANAVEX 3-71, which uses ligands that activate sigma-1 and M1 muscarinic receptors to treat AlzheimerÂ’s disease; ANAVEX 1-41, a sigma-1 agonist that protects nerve cells from degeneration or death; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain.

Anavex Life Sciences Corp. (NASDAQ:AVXL) Ratings Coverage
Among 2 analysts covering Anavex Life Sciences Corp. – Common Stock (NASDAQ:AVXL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Anavex Life Sciences Corp. – Common Stock has $16.00 highest and $10.00 lowest target. $13’s average target is 362.63% above currents $2.81 stock price. Anavex Life Sciences Corp. – Common Stock had 3 analyst reports since June 18, 2019 according to SRatingsIntel.

More notable recent Anavex Life Sciences Corp. (NASDAQ:AVXL) news were published by: Benzinga.com which released: “25 Stocks Moving in Friday’s Pre-Market Session – Benzinga” on September 27, 2019, also Globenewswire.com with their article: “Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 – GlobeNewswire” published on September 05, 2019, Globenewswire.com published: “Anavex Life Sciences Announces First Patient Dosed in Extension Study to its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients for Rett Syndrome – GlobeNewswire” on June 25, 2019. More interesting news about Anavex Life Sciences Corp. (NASDAQ:AVXL) were released by: Seekingalpha.com and their article: “Alzheimer’s Disease: Anavex 2-73 And The Long Road Home – Seeking Alpha” published on November 08, 2017 as well as Globenewswire.com‘s news article titled: “Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates – GlobeNewswire” with publication date: August 07, 2019.

https://yorkreporter.com/2019/10/20/stock-news/what-will-happen-to-anavex-life-sciences-corp-nasdaqavxl-next-the-stock-has-decline-in-shorts/

Good luck and GOD bless,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist